Researchers at the Hackensack Meridian Center for Discovery and Innovation (CDI) and Georgetown University’s Lombardi Comprehensive Cancer Center have identified “adipomes”—extracellular vesicles released by fat tissue—as active drivers in the spread of triple-negative breast cancer (TNBC). By isolating these vesicles, the team discovered they deliver a “lipid code” that reprograms cancer cells to form invadopodia, the protein tentacles that allow tumors to invade surrounding tissue and metastasize to other organs.
How do fat cells accelerate breast cancer growth?
Scientists have long viewed fat tissue surrounding a tumor as a passive reservoir for lipids. According to the study published in npj Breast Cancer, this view is incorrect. Lead author Hariprasad Thangavel, Ph.D., and senior author Jyothi Nagajyothi, Ph.D., found that tumor cells “hijack” these adipocytes, forcing them to release adipomes. These vesicles act as cellular messengers, triggering stress-response signaling and boosting protein synthesis within the cancer cells. This process effectively primes the tumor to break through the stroma, the supportive tissue of the breast, and begin the metastatic cascade.
The research team developed a proprietary purification technique to isolate pure adipomes from bodily fluids. This method, which overcame a major technical barrier in cancer research, is currently the subject of a patent application filed by Hackensack Meridian Health.
Why is this discovery significant for future treatments?
Current treatment options for TNBC are limited due to the cancer’s aggressive nature and tendency to metastasize early. By identifying the specific signaling axis between fat cells and tumor cells, researchers believe they have found a new target for drug development. Rather than just treating the tumor, future therapies could potentially interrupt the “lipid code” communication, stopping the cancer from ever developing the invadopodia necessary to spread. This strategy could allow clinicians to intervene at much earlier stages of the disease.
How does this research compare to previous understandings of metastasis?
Previous oncology studies focused heavily on the mechanics of invadopodia—the protein structures that degrade the body’s defenses. While scientists have observed these “tentacles” for years, they did not fully understand what triggered their formation in the early stages of TNBC. The work by the CDI and Georgetown team shifts the focus to the tumor microenvironment (TME). By connecting the source of the trigger (adipomes) to the physical result (invadopodia), this research provides a clearer timeline of how the cancer becomes metastatic.
Pro Tip: Monitoring the Tumor Microenvironment
Clinicians are increasingly looking at the TME, not just the cancer cells themselves, to predict patient outcomes. Understanding how local fat deposits interact with specific tumor types may eventually lead to more personalized oncology screenings.
Frequently Asked Questions
What is triple-negative breast cancer (TNBC)?
TNBC is a type of breast cancer that does not have estrogen receptors, progesterone receptors, or excess HER2 protein. Because it lacks these common targets, it is often more aggressive and harder to treat than other forms of breast cancer.
What are adipomes?
Adipomes are microscopic extracellular vesicles released by fat tissue. According to the study, they function as communication tools that can reprogram nearby cells, including cancer cells.
Can this discovery lead to a cure?
While this study identifies a new therapeutic target, it is a preclinical finding. Further research and clinical trials are required to determine if interrupting the adipocyte-tumor signaling axis will effectively stop metastasis in human patients.
Stay informed on the latest breakthroughs in oncology research. Subscribe to our newsletter for weekly updates on clinical trials and cancer research developments.
